Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2008 by NatImmune A/S.
Recruitment status was:  Recruiting
Information provided by:
NatImmune A/S Identifier:
First received: March 25, 2008
Last updated: March 26, 2008
Last verified: March 2008
As many as 85 % of renal transplant patients may suffer from viral warts with a high degree of treatment resistance. Promising results of hLAC (human lactalbumin complex with lipid) point to a beneficial effect without noticeable side effects of bLAC (bovine lactalbumin complex with lipid). The aim of first clinical trial with bLAC is to show proof of concept in treatment of cutaneous wart lesions on hands and/or feet after local administration of bLAC in two dose groups to immune suppressed, kidney transplanted patients.

Condition Intervention Phase
Cutaneous Warts
Drug: bLAC
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: bLAC - A Phase II Double-Blind, Placebo Controlled, Clinical Proof of Concept Trial of the Efficacy of 8 Weeks Treatment of Cutaneous Warts With bLAC in Immune Suppressed, Kidney Transplanted Patients

Resource links provided by NLM:

Further study details as provided by NatImmune A/S:

Primary Outcome Measures:
  • Reduction in the area of wart lesions located on fingers and/or palms and/or toes and/or soles of the feet, measured by an objective method by drawing of individual lesions [ Time Frame: Prospective ]

Secondary Outcome Measures:
  • Clearance of index wart lesions. Time to clearance of warts. Recurrence rate of previously cleared wart lesions. Occurrence of new warts.overall changes of index warts lesions. Safety and tolerability. [ Time Frame: Prospective ]

Estimated Enrollment: 120
Study Start Date: March 2008
Estimated Study Completion Date: February 2009
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
bLAC high dose
Drug: bLAC
bLAC high and low dose and placebo
Active Comparator: 2
bLAC low dose
Drug: bLAC
bLAC high and low dose and placebo
Placebo Comparator: 3 Drug: Placebo


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cutaneous warts on ingers and/or palms and/or toes and/or soles of feet
  • Common warts and mosaic warts, diagnosed by an experienced dermatologist
  • Solitary wart lesions or 2 or more lesions per patient
  • Lesions present for more than 6 months
  • Men or women, aged 18 or above
  • History of kidney transplantation and immune suppressive therapy after transplant
  • Concomitant immune suppressive therapy stable for 6 months prior to randomization
  • Agreement from patient to allow photographs to be taken and used as part of trial data documentation (2 centres)
  • Women of childbearing potential must have negative pregnancy test at screening and must use adequate contraception
  • Ability to comply with requirements of trial
  • Written informed consent

Exclusion Criteria:

  • Verruca plana lesions
  • Suspected allergy to milk verified by serum analysis of IgE towards cow milk
  • Breastfeeding
  • Any local medication for any purpose other than wart treatment in target area during 4 weeks prior to randomization and during treatment period
  • Concomitant treatment with other wart therapies two weeks prior to randomization and during trial period
  • Intolerance towards bovine alpha-lactalbumin, oleic acid or any excipient in the formulation
  • Known HIV infection or any current uncontrolled infection
  • Any chronic or acute skin condition susceptible of interfering with evaluation of drug effect in this trial
  • Participation in any investigational trial or use of any investigational drug within 30 days prior to inclusion in this trial
  • Any health problems which according to Investigator's clinical judgment will make the patient unsuitable for inclusion in the trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00644579

Contact: Claus Zachariae, MD, Chief Physician +4539773203

Dermatology Clinic, Vesterbro Recruiting
Aalborg, Denmark, DK-9000
Principal Investigator: Henrik Sølvsten, MD         
Marselisborg University Hospital Recruiting
Aarhus C, Denmark, DK-8000
Principal Investigator: Mette S Deleuran, MD         
Bispebjerg University Hospital Recruiting
Copenhagen NV, Denmark, DK-2400
Principal Investigator: Merete Hædersdal, MD         
Gentoftte Amtssygehus Recruiting
Hellerup, Denmark, DK-2900
Principal Investigator: Claus Zachariae, MD         
Odense University Hospital Recruiting
Odense, Denmark, DK-5000
Principal Investigator: Henrik Lorentzen, MD         
Sponsors and Collaborators
NatImmune A/S
Principal Investigator: Claus Zachariae, MD Gentofte Amtssygehus
  More Information

Responsible Party: NatImmune A/S, NatImmune Identifier: NCT00644579     History of Changes
Other Study ID Numbers: CL-1205
EudraCT number: 2007-006738-33
Study First Received: March 25, 2008
Last Updated: March 26, 2008

Keywords provided by NatImmune A/S:
Cutaneous warts in immune suppressed, kidney transplant patients

Additional relevant MeSH terms:
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases processed this record on April 25, 2017